Understanding FDA's Reasons For Nonapproval: A Systematic Review Of Complete Response Letters In Cell And Gene Therapy

FDA Complete Response Letters offer a valuable window into the regulatory issues that can delay approval of cell and gene therapies. In a new Cytotherapy publication, ElevateBio’s Cindy Riggins, Vice President, CMC Regulatory Affairs, and Eugene Babcock, Director, Regulatory, examine recurring themes within these letters and their implications for development programs. Their analysis highlights the importance of complete, consistent CMC information, strong manufacturing controls, and inspection readiness well before submission. By understanding where applications commonly fall short, development teams can identify potential gaps earlier, strengthen regulatory planning, and build more robust submissions.

Explore how proactive CMC preparation and early attention to inspection requirements can help reduce regulatory risk and support more efficient paths toward approval.